Current filters:

Boehringer Ingelheim

151 to 160 of 1235 results

More highlights from ASCO for: Eisai's Halaven; Boehringer's nintedanib; and Lilly's Alimta


Among further highlights from the ongoing American Society of Clinical Oncology (ASCO) meeting in Chicago,…

AlimtaBoehringer IngelheimEisaiHalavenLillynintedanibOncologyPharmaceuticalResearch

Boehringer Ingelheim gets FDA warning letter on cGMP failures


German family-owned drug major Boehringer Ingelheim today (May 22) revealed that the US Food and Drug…

Boehringer IngelheimGenericsPharmaceuticalProductionRegulation

Boehringer Ingelheim transitions to propellant-free Combivent Respimat; names new BMD member


German family-owned drug major Boehringer Ingelheim said today (May 17) that it is updating health care…

Boehringer IngelheimCombivent RespimatManagementPharmaceuticalProductionRespiratory and Pulmonary

US FDA approves companion diagnostic for Tarceva, and new indication for the Roche drug


The US Food and Drug Administration late yesterday (May 14) approved Swiss drug major Roche (ROG: SIX)…

Boehringer IngelheimNorth AmericaOncologyPharmaceuticalQiagenRegulationRocheTarcevaTomtovok

Surveys reveal opportunity for medical community to fully embrace biomarker testing in lung cancer


Results of two surveys that explored how pulmonologists and pathologists are incorporating biomarker…

Boehringer IngelheimNorth AmericaOncologyPharmaceuticalResearch

Boehringer Ingelheim joins SGC for further research into incurable diseases


German family-owned drug major Boehringer Ingelheim has joined the Structural Genomics Consortium (SGC),…

Boehringer IngelheimPharmaceuticalRare diseasesResearch

Oxford BioThera and Boehringer Ingelheim collaborate; Milestone for Heptares


The UK's Oxford BioTherapeutics (OBT) and family-owned German drug major Boehringer Ingelheim have entered…

Boehringer IngelheimHeptares TherapeuticsLicensingNeurologicalOncologyOxford BioTherapeuticsPharmaceuticalResearchTakeda Pharmaceuticals

Boehringer Ingelheim Venture Fund invests in Eyevensys


Paris, France-based Eyevensys, a developer of a new process for non-viral gene therapy using electrotransfer…

Boehringer IngelheimEyevensysFinancialMergers & AcquisitionsOphthalmicsPharmaceutical

US pulmonologists view refractory asthma patient treatment with biosimilar Xolair by end-2018


US pulmonologists surveyed by health care advisory firm Decision Resources estimate that only 19% percent…

BiotechnologyBoehringer IngelheimGenentechGenericsMarkets & MarketingNorth AmericaNovartisPfizerRespiratory and PulmonarySpirivaXolair

151 to 160 of 1235 results

Back to top